Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | AGER | Q15109 | 2/20 | 0.34 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283481 | 0.97 | LTA4H (0.36) | LTA4HPTGS2HRH4HRH3KCNH2 | |
| SCHEMBL13100561 | 0.95 | LTA4H (0.39) | LTA4HPTGS2HRH4HRH3KCNH2 | |
| SCHEMBL1283326 | 0.95 | LTA4H (0.39) | LTA4HPTGS2HRH4HRH3KCNH2 | |
| SCHEMBL1283682 | 0.94 | AGER (0.37) | LTA4HPTGS2HRH4HRH3KCNH2 | |
| SCHEMBL1283161 | 0.94 | AGER (0.37) | LTA4HPTGS2HRH4HRH3KCNH2 | |
| SCHEMBL1283608 | 0.94 | AGER (0.37) | LTA4HPTGS2HRH4HRH3KCNH2 | |
| SCHEMBL1283502 | 0.94 | AGER (0.37) | LTA4HPTGS2HRH4HRH3KCNH2 | |
| SCHEMBL1283637 | 0.94 | AGER (0.37) | LTA4HPTGS2HRH4HRH3KCNH2 | |
| SCHEMBL1283823 | 0.94 | AGER (0.37) | LTA4HPTGS2HRH4HRH3KCNH2 | |
| SCHEMBL1615260 | 0.90 | AGER (0.39) | AGERTHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AGER, S100A4, S100B | LTA4H 2586/4885PTGS2 1181/4885HRH4 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.